Curatis Holding AG Overview
Pro stress-test →Curatis Holding AG is a Swiss specialty pharmaceutical company focused on acquiring, developing, and commercializing innovative medicines for rare and specialty care diseases. Founded in 2002 and listed on SIX Swiss Exchange since early 2024, Curatis operates through both a profitable distribution business for orphan drugs and a pipeline of proprietary drug candidates in clinical development.
Strategic Profile
Pro stress-test →Curatis has differentiated itself as a leader in the Swiss orphan drug market with exclusive distribution rights for 40+ products and a growing presence planned across major European markets. The company combines immediate revenue generation from its distribution business with high-value development opportunities, particularly its Phase IIb lead candidate C-PTBE-01 for peritumoral brain edema. Recent financials show 30% distribution sales growth and a strategic pivot toward geographic and product portfolio expansion.
Competitive Landscape
Pro stress-test →Curatis competes in the niche orphan drug space against larger pharmaceutical distributors and integrated biotech companies. Direct competitors include Recordati (orphan drugs division), Santhera Pharmaceuticals, and Actelion (acquired by J&J). Unlike larger competitors, Curatis maintains focused positioning in Switzerland with European expansion ambitions, competing through specialized expertise and direct relationships rather than scale.
Industry Context
Curatis Holding AG operates in Specialty Pharmaceuticals - Orphan/Rare Diseases.
Key facts
Founded: 2002 · Headquarters: Liestal, Switzerland · Employees: ~8 · Revenue: CHF 6.9M (2024, 8-month post-acquisition) · Market cap: CHF 58.16M